Table 2 Relationship between demographic or clinical characteristics and final diagnosis: cancer/noncancer in TN patients. Descriptive data are presented as the number (percent) or average ± standard deviation (±SD).

From: Patients with III and IV category of the Bethesda System under levothyroxine non-suppressive therapy have a lower rate of thyroid malignancy

Parameters

Cancer (n = 97)

Noncancer (n = 435)

p-value

Gender:

woman

83 (85.6)

354 (81.4)

0.33

man

14 (14.4)

81 (18.6)

Age (years)

50.40 ± 18.11

49.29 ± 15.66

0.542

Age:

<45 year

40 (41.2)

169 (38.9)

0.663

≥45 year

57 (58.8)

266 (61.1)

Category of Bethesda:

III

14 (14.4)

127 (29.2)

0.003*

IV

83 (85.6)

308 (70.8)

Thyroid hormone therapy:

yes

20 (20.6)

156 (35.9)

0.004*

no

77 (79.4)

279 (64.1)